Cardinal Health Inc (CAH) raises EPS guidance despite a 4% revenue decline, driven by robust pharmaceutical segment ...

Stocks to Buy or Sell. In this article, we are going to take a look at where Cardinal Health, Inc. (NYSE:CAH) stands against ...

Bank of America Securities analyst Allen Lutz maintained a Buy rating on Cardinal Health (CAH – Research Report) today. The company’s shares ...

Q2 2025 Earnings Call Transcript January 30, 2025 Cardinal Health, Inc. beats earnings expectations. Reported EPS is $1.93, ...

Baird raised the firm’s price target on Cardinal Health (CAH) to $154 from $149 and keeps an Outperform rating on the shares. Invest with ...

Hello, and welcome to the Second Quarter Fiscal Year 2025 Cardinal Health Inc. Earnings Conference Call. My name is George, and I'll be coordinator for today's event. Please note, this conference is ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.

According to the average brokerage recommendation (ABR), one should invest in Cardinal (CAH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' ...

Cardinal Health Inc (CAH) stock saw a decline, ending the day at $127.73 which represents a decrease of $-3.00 or -2.29% from the prior close of $130.73. The stock opened at $130.84 and touched a low ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases, has been navigating a complex landscape of ...

Cardinal Health (NYSE:CAH – Free Report) had its price objective hoisted by JPMorgan Chase & Co. from $132.00 to $142.00 in a ...